// App-Quantinova.ai

e21032 : SWOG S1404: A phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanoma.

Researchers

Presenter

  • Kenneth F. Grossmann

Principal Investigators

  • Megan Othus

  • Ahmad A. Tarhini

  • Sapna Pradyuman Patel

  • James Moon

  • Vernon K. Sondak

  • John M. Kirkwood

  • Antoni Ribas

Medical Centers

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • SWOG Statistical Center, Seattle, WA

  • University of Pittsburgh Cancer Institute, Pittsburgh, PA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Southwest Oncology Group Statistical Center, Seattle, WA

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA

  • UCLA and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Melanoma

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Interferon

Drug/Treatment

  • Interferon

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved